Silvia Favilli

Dr. Silvia Favilli

Department of Pediatric Cardiology, Meyer Hospital, 50139 Florence, Italy

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1995 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AZAlfredo Zuppiroli
Alfredo Zuppiroli
MRMichael Rinaldi
Michael Rinaldi
RKRandi Kramer-Fox
Randi Kramer-Fox
SFSilvia Favilli
Silvia Favilli
MRMary J. Roman
Mary J. Roman
RDRichard B. Devereux
Richard B. Devereux

1 June 2018 in JAMA Cardiology
Verified
Journal Article
Closed access
PDF file
NMNiccolò Maurizi
Niccolò Maurizi
SPSilvia Passantino
Silvia Passantino
GSGaia Spaziani
Gaia Spaziani
FGFrancesca Girolami
Francesca Girolami
AAAnna Arretini
Anna Arretini
IOIacopo Olivotto
Iacopo Olivotto
Importance Predictors of lethal arrhythmic events (LAEs) after a pediatric diagnosis of hypertrophic cardiomyopathy (HCM) are unresolved. Existing algorithms for risk stratification are limited to patients older than 16 years because of a lack of data on younger individuals. Objective To describe the long-term outcome of pediatric-onset HCM and identify age-specific arrhythmic risk factors. Design, Setting, and Participants This study assessed patients with pediatric-onset hypertrophic cardiomyopathy diagnosed from 1974 to 2016 in 2 national referral centers for cardiomyopathies in Florence, Italy. Patients with metabolic and syndromic disease were excluded. Exposures Patients were assessed at 1-year intervals, or more often, if their clinical condition required. Main Outcomes and Measures Lethal arrhythmic events (LAEs) and death related to heart failure. Results Of 1644 patients with HCM, 100 (6.1%) were 1 to 16 years old at diagnosis (median [interquartile range], 12.2 [7.3-14.1] years). Of these, 63 (63.0%) were boys. Forty-two of the 100 patients (42.0%) were symptomatic (defined as an New York Heart Association classification higher than 1 or a Ross score greater than 2). The yield of sarcomere gene testing was 55 of 70 patients (79%). During a median of 9.2 years during which a mean of 1229 patients were treated per year, 24 of 100 patients (24.0%) experienced cardiac events (1.9% per year), including 19 LAEs and 5 heart failure–related events (3 deaths and 2 heart transplants). Lethal arrhythmic events occurred at a mean (SD) age of 23.1 (11.5) years. Two survivors of LAEs with symptoms of heart failure experienced recurrent cardiac arrest despite an implantable cardioverter defibrillator. Risk of LAE was associated with symptoms at onset (hazard ratio [HR], 8.2; 95% CI, 1.5-68.4;P = .02) and Troponin I or Troponin T gene mutations (HR, 4.1; 95% CI, 0.9-36.5;P = .06). Adult HCM risk predictors performed poorly in this population. Data analysis occurred from December 2016 to October 2017. Conclusions and Relevance Pediatric-onset HCM is rare and associated with adverse outcomes driven mainly by arrhythmic events. Risk extends well beyond adolescence, which calls for unchanged clinical surveillance into adulthood. In this study, predictors of adverse outcomes differ from those of adult populations with HCM. In secondary prevention, the implantable cardioverter defibrillator did not confer absolute protection in the presence of limiting symptoms of heart failure.

24 July 2019 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
YAYoung Cardiologists Area On Behalf Of Cardiovascular Prevention Area
Young Cardiologists Area On Behalf Of Cardiovascular Prevention Area
MAMaurizio Giuseppe ABRIGNANI
Maurizio Giuseppe ABRIGNANI
FLFabiana Lucà
Fabiana Lucà
SFSilvia Favilli
Silvia Favilli
MBManuela Benvenuto
Manuela Benvenuto
HFHeart Care Foundation
Heart Care Foundation

1 November 1994 in American Heart Journal
Verified
Journal Article
Closed access
AZAlfredo Zuppiroli
Alfredo Zuppiroli
FMFabio Mori
Fabio Mori
SFSilvia Favilli
Silvia Favilli
ABAlessandro Barchielli
Alessandro Barchielli
GCGiorgio Corti
Giorgio Corti
ADAlberto Dolara
Alberto Dolara

30 September 2012 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
ABArianna Bocelli
Arianna Bocelli
SFSilvia Favilli
Silvia Favilli
IPIva Pollini
Iva Pollini
RBRoberta Margherita Bini
Roberta Margherita Bini
PBPiercarlo Ballo
Piercarlo Ballo
AZAlfredo Zuppiroli
Alfredo Zuppiroli

1 February 2019 in International Journal of Cardiology
Verified
Journal Article
Open access
ABAlice Brambilla
Alice Brambilla
SFSilvia Favilli
Silvia Favilli
IOIacopo Olivotto
Iacopo Olivotto
GCGiovanni Battista Calabri
Giovanni Battista Calabri
GPGiulio Porcedda
Giulio Porcedda
MDMaria Alice Donati
Maria Alice Donati
Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like (MELAS) syndrome is a rare condition with heterogeneous clinical presentation. Cardiac involvement commonly develops during adulthood, comprising both structural and conduction/arrhythmic abnormalities; early paediatric onset has rarely been reported. We describe the clinical profile, outcome and clinical implication of MELAS-associated cardiomyopathy at a tertiary referral centre. From 2000 to 2016 we enrolled 21 patients affected by genetically-proven MELAS. Patients were followed-up at least annually over a mean of 8.5 years. All patients carried the MT-TL1 3243A>G mutation. Cardiac involvement was documented in 8 (38%) patients (three 18 years.